In the present study, we investigated the potential of N-BNP (N-terminal B-type natriuretic peptide) as a prognostic marker for risk of CV (cardiovascular) events, overall mortality and progression to ESRD (end-stage renal disease) in a cohort of 83 pre-dialysis CKD (chronic kidney disease) patients without clinical evidence of heart failure. During the study, ten patients reached the combined end point of overall mortality and/or CV event. Univariate factors associated with the combined end point were plasma N-BNP (P < 0.0005), creatinine (P < 0.002), systolic blood pressure (P < 0.009) and age (P < 0.015). N-BNP levels were higher in patients with CV events (P < 0.0005). Cox model regression analysis yielded log 10 N-BNP (hazard ratio, 9.608; P < 0.007) and pre-existing CV disease (hazard ratio, 4.571; P < 0.029) as independent predictors of overall mortality or CV events. Kaplan-Meier analysis curves for the subgroup with supramedian creatinine levels (225 µmol/l) showed significant separation of the curves stratified for plasma N-BNP levels above and below the group median (291 pmol/l) for all end points. Receiver-operatorcharacteristic curves for N-BNP (355 pmol/l cut-off) demonstrated a specificity of 65.8 % at a sensitivity of 100 % for predicting CV events/overall mortality. The measurement of plasma N-BNP may aid in the risk stratification of pre-dialysis CKD patients. The high sensitivity and negative predictive value (100 %) may enable the selection of patients who could safely be excluded from further investigations, resulting in better focusing of resources.
INTRODUCTION
The risk of CV (cardiovascular) disease in patients with CKD (chronic kidney disease) is far in excess of that in the general population [1, 2] . In ESRD (end-stage renal disease), mortality from CV disease is 20 times higher [2] and, although there is less epidemiological data in patients with renal insufficiency, the burden of CV disease may actually be greater [1] .
Early diagnosis and treatment of cardiac disease may improve survival in CKD patients. LVMI (left ventricular mass index) is a good prognostic indicator for survival in CKD [3] [4] [5] . However, both two-dimensional echocardiographic and three-dimensional MRI (magnetic resonance imaging) techniques to estimate LVMI are impractical screening tests in routine clinical practice and, thus, a reliable non-invasive biochemical screening test would be a useful alternative to predict increased CV risk in this population.
Members of the natriuretic peptide system [ANP (atrial natriuretic peptide) and BNP (brain natriuretic peptide)] have been studied as possible markers of increased CV risk. In the general population, BNP provides useful prognostic information [6] [7] [8] , and in nonuraemic patients BNP has been shown to act as a diagnostic marker for left ventricular hypertrophy and left and right ventricular dysfunction [9, 10] and heart failure [10] . In addition, BNP acts as a predictor of mortality in heart failure, post-myocardial infarction, unstable angina, cor pulmonale and primary pulmonary hypertension [10] . Several studies have examined BNP as a potential prognostic marker for cardiovascular mortality in dialysis patients [11] [12] [13] . Zoccali et al. [11] studied dialysis patients and found that BNP was an independent predictor of death. Similarly, Cataliotti et al. [12] reported that BNP was significantly higher in dialysis patients who died of CV causes compared with survivors and was significantly associated with greater risk of CV death. In addition, a further study in dialysis patients found that BNP, LVMI and CRP (C-reactive protein) were powerful independent predictors of cardiac death [13] .
However, the prognostic utility of BNP has not been as well demonstrated in the early stages of kidney disease when CV disease processes may be more amenable to modification by therapeutic interventions. There is one recent study by Takami et al. [14] reporting on nondialysis-dependent CKD patients in whom multivariate Cox regression analysis showed high plasma BNP as the strongest predictor for heart failure events. The aim of the present study was to determine whether N-BNP (Nterminal BNP) acts as a useful prognostic marker for overall mortality and CV events in patients with CKD. The relationship between N-BNP and renal disease was also explored.
MATERIALS AND METHODS

Patients
Patients (n = 83) with CKD and without clinical evidence of heart failure were recruited to the present study from nephrology outpatient clinics of the University Hospitals of Leicester NHS Trust from June 2000 to July 2002. For the purpose of study analysis, the study was closed on 31 March 2004. Heart failure was excluded based on absence of heart failure symptoms and physical signs of raised jugular venous pressure or bibasal crepitations on auscultation of the chest. Patients with a known diagnosis of heart failure or on treatment for heart failure were also excluded. The presence of pre-existing CV disease aside from heart failure was determined by retrospective review of the patients' clinical notes as well as the PROTON information system employed by the nephrology service. All patients were in sinus rhythm at the time of the study.
All subjects gave their informed consent, and the study was approved by the Leicestershire Local Research Ethics Committee.
Protocol
Height, weight and BMI (body mass index) were recorded at the first visit. Baseline GFR (glomerular filtration rate) was measured by a plasma iodohexol clearance technique [15] for all patients except 11 subjects who had 24-h creatinine clearance measurements instead. Blood samples for haemoglobin, creatinine, total cholesterol and plasma N-BNP were collected at baseline. These blood samples were obtained after the subject had rested in a semi-recumbent position for at least 10 min. For N-BNP, samples were collected into chilled tubes containing EDTA and Trasylol (aprotinin), centrifuged and frozen within 30 min. The plasma was stored at − 80
• C. Plasma N-BNP was measured by an in-house noncompetitive immunoluminometric assay on unextracted plasma [16] . The capture antibody was directed to the C-terminal of human N-BNP and the biotinylated Nterminal-directed antibody was the detector antibody. Aliquots (10-20 µl) of samples or N-BNP standards were incubated in ELISA plate wells coated with the Cterminal antibody (100 ng/well) together with 100 µl of the biotinylated N-terminal antibody for 24 h at 4
• C. Detection was with streptavidin (Chemicon International, Harrow, Middx., U.K.) labelled with methylacridinium ester (5 × 10 6 relative light units/ml) added to each well. Plates were then read on a Dynex Technologies MLX Luminometer, with sequential injections of 100 µl of 0.1 M nitric acid (with H 2 O 2 ) and then 100 µl of NaOH (with cetyl ammonium bromide), integrating the emitted light over 2 s. The lower limit of detection was 0.3 fmol/ml (pmol/l) with no significant cross-reactivity with N-ANP (N-terminal ANP), BNP or CNP (C-type natriuretic peptide).
Patients subsequently continued with their usual follow-up at the nephrology outpatient clinics. Following the close of the study, end points were recorded from a number of sources, including hospital medical records, the nephrology department information system (PROTON) and the registrar for births, marriages and deaths in Leicestershire and Northamptonshire. Causes of death were ascertained from death certificates completed independently of the study investigators by the patients' attending doctors or from coroners' reports. For the analysis of renal disease progression, the most recent serum creatinine measurements available at the time of reaching a study end point or within 6 months of the close of the study were employed.
Outcome measures
Doubling of serum creatinine was considered to occur when the creatinine level reached twice that of the baseline value or was within 2 times minus 10 % of the baseline value, confirmed by a subsequent serum creatinine measurement. ESRD was defined by the need for longterm dialysis or renal transplantation.
Cardiovascular mortality was defined as death caused by cardiac events, such as sudden death, myocardial ischaemia or heart failure, and death due to cerebrovascular incidents. Death was recorded in terms of overall mortality which includes deaths due to both CV and non-CV causes. Only major CV events were recorded and these included non-fatal myocardial infarction, non-fatal strokes, new-onset arrhythmias associated with haemodynamic compromise and hospitalization for unstable angina or heart failure.
Statistical analysis
Data were analysed using SPSS version 11.0 (SPSS, Chicago, IL, U.S.A.). Values for the clinical continuous variables are expressed as means (S.D.). Medians (ranges) are reported for plasma N-BNP levels, and comparisons were performed using the Mann-Whitney U test. Areas under the ROC (receiver-operator-characteristic) curves and their associated S.E.M. were estimated. N-BNP values were normalized by log 10 transformation for Cox proportional hazards modelling. Kaplan-Meier survival curves were constructed using N-BNP and serum creatinine values below or above the median.
RESULTS
Patient characteristics
The main demographic and clinical characteristics of the patients included in the study are shown in Table 1 . The aetiology of renal disease varied, and there was a range of severity of CKD, although the distribution was skewed with overall more than 90 % of patients in CKD stage 3-5. There was a larger proportion of patients with more advanced renal failure in the group with end points, but this difference was adjusted for in subsequent data analysis. Overall, 71 patients (85.5 %) had hypertension and 25 (30 %) had prevalent ischaemic heart disease or some other form of vascular disease. The proportion of subjects with pre-existing macrovascular disease was higher in the group with end points (P < 0.001, as determined by χ 2 test). A total of 77 patients (92.8 %) were on antihypertensive medication, and 44 patients (53.0 %) were receiving ACEi (angiotensin-converting-enzyme inhibitor) or ARB (angiotensin II receptor blocker), or a combination of the two. Almost one-third of the patients were on statin therapy, and 12.0 % were receiving aspirin. Again, there were differences between the groups in terms of ACEi/ARB and diuretic use, but this did not appear to exert an influence on outcome in subsequent analysis.
N-BNP, overall mortality and CV events
During the mean follow-up period of 32.3 months, six non-fatal CV events occurred. Overall, eight patients died and five of these deaths were directly due to CV causes. A total of ten patients reached the combined end point of overall mortality and/or CV event. As evident from the box-whisker plots in Figure 1 , plasma N-BNP levels were higher in this subgroup of patients compared with those who survived without any CV events. The difference between the mean plasma N-BNP levels in the subgroup with overall mortality and/or CV events and the event-free patients was significant [1166.5 (363.5-2924.1) compared with 244.9 (0.3-4548.7) pmol/l; P < 0.0005; values are medians (range)].
The Mann-Whitney U test identified univariate factors associated with the combined end point of overall mortality and/or CV events to be plasma N-BNP, baseline creatinine, SBP (systolic blood pressure) and age in the order of significance P < 0.0005, P < 0.002, P < 0.009 and P < 0.015 respectively. Results of the same analysis performed separately for overall mortality and CV events yielded similar results. Diuretic and ACEi therapy were not found to have any significant effect.
Cox model regression analysis for prediction of overall mortality/CV events [using log 10 N-BNP, log 10 creatinine, pre-existing CV disease, age, gender, BMI, SBP and DBP (diastolic blood pressure)] identified log 10 N-BNP (hazard ratio, 9.608; P < 0.007) and pre-existing CV disease (hazard ratio, 4.571; P < 0.029) as independent predictors of overall mortality or CV events.
Since there was a clear relationship between the eventrate and level of baseline creatinine for the KaplanMeier survival analysis, we stratified the study population based on baseline creatinine levels above and below the median (225 µmol/l). Patients were then stratified further according to plasma N-BNP levels above and below the median N-BNP of 291 pmol/l. No events occurred in those whose creatinine levels were below the median. The Kaplan-Meier survival analysis curves for the subgroup with baseline creatinine levels above the median are shown in Figure 2 . By 12 months, there was significant separation of the curves according to infra-or supramedian plasma N-BNP levels (P < 0.008 for log trend in those with supramedian serum creatinine levels).
The ROC curves for log creatinine and N-BNP are shown in Figure 3 , and the mean (S.E.M.) areas under the ROC curves for N-BNP and log creatinine were 0.862 (0.046) and 0.810 (0.051) respectively. At a cut-off value of 355 pmol/l, the sensitivity and specificity of N-BNP for predicting a CV event or overall mortality were 100 % and 65.8 % respectively. The positive and negative predictive values were 28.6 % and 100 % respectively, an overall accuracy of 69.9 %.
Of the ten patients who died or had a CV event, five (50 %) were on ACEi and three (30 %) were on statins. Of the 35 patients with N-BNP above the cut-off value of 355 pmol/l, only a proportion were prescribed ACEi or statins [16 (45.7 %) and 13 (37.1 %) respectively].
Patients with end points were less likely to be on ACEi/ARB and diuretics. Such drugs could potentially affect plasma N-BNP levels. This was examined using the univariate general linear model procedure to examine factors that could influence plasma N-BNP levels. For the end point of death/CV event, this was the only independent factor influencing N-BNP levels (P < 0.001), with no interaction with prescription of ACEi/ARB or diuretics. Similarly, for the end point of death/CV event/ dialysis/doubling creatinine, this was the only independent factor influencing N-BNP levels (P < 0.0005), with no drug therapy interaction.
Figure 1 Box-whisker plots for plasma concentrations of N-BNP in patients with a CV event or overall mortality and in event-free patients
The line indicates the median, the box is the interquartile range, and the whiskers are the 2.5 and 97.5 centiles. The line indicates the median, the box is the interquartile range, and the whiskers are the 2.5 and 97.5 centiles.
N-BNP and renal disease progression
During the course of this study, 12 patients doubled their serum creatinine and ten patients progressed to ESRD, a total of 22 patients. Figure 4 shows that plasma N-BNP levels were significantly higher in those reaching the end point of doubling of serum creatinine or dialysis compared with the remaining patients. The median (range) plasma N-BNP level for patients with doubling of serum creatinine or dialysis was 663.5 (24.7-4548.7) pmol/l compared with 244.9 (0.3-2924.1) pmol/l in event-free subjects (P < 0.008). There were no separate univariate or multivariate analyses for N-BNP and doubling of creatinine or dialysis as this was a secondary end point of the study.
N-BNP and the composite end point of doubling of serum creatinine, dialysis, overall mortality or CV events
Consistent with the above findings, plasma N-BNP levels were significantly higher in patients who encountered a doubling of serum creatinine, dialysis, overall mortality or a CV event ( Figure 5 ). A greater proportion of patients with this end point had pre-existing cardiovascular disease (P < 0.01, as determined by χ 2 test). Median (range) plasma N-BNP was 697.1 (24.7-4548.7) pmol/l in those who suffered this combined end point (n = 28) compared with 155.1 (0.3-2499.1) pmol/l (P < 0.0005) in those who were event-free.
Multivariate Cox regression analysis for the composite end point was performed with the predictor variables log 10 N-BNP, age, gender, BMI, SBP and DBP (Table 2) . Log 10 serum creatinine was not utilized as this would, by definition, have been a major determinant of some components of the end point (i.e. doubling of serum The line indicates the median, the box is the interquartile range, and the whiskers are the 2.5 and 97.5 centiles.
Table 2 Cox regression analysis for doubling creatinine, dialysis, overall mortality or CV event
Cox regression analysis of the predictors of overall mortality/CV event/ dialysis/doubling of creatinine using age, gender, pre-existing cardiovascular disease, log 10 plasma N-BNP, SBP and DBP. P values and hazard ratios are reported for the predictor variables and factors. creatinine or dialysis). Log 10 N-BNP emerged as the most significant independent predictive factor in regression analysis. Kaplan-Meier analysis of survival patterns was done by first stratifying patients into two groups according to plasma N-BNP levels above or below the median value [ Figure 6 (left-hand panel) ]. Patients with supramedian N-BNP levels had more events over this period of observation (P < 0.03). Analysis performed for patients with baseline creatinine values below [ Figure 6 (middle panel)] and above the median [ Figure 6 (righthand panel)] revealed that at infra-median serum creatinine values, N-BNP was not a useful predictor. In the supra-median serum creatinine stratum, the curves stratified according to median N-BNP levels diverged significantly (P = 0.04).
DISCUSSION
The present study has reported for the first time that plasma N-BNP levels appear to predict the risk of CV events and overall mortality in a population of nondialysis-dependent CKD patients. By virtue of its selection criteria, none of the patients in the present study had signs or symptoms to suggest overt cardiac failure and it is therefore tempting to speculate that elevations in N-BNP might be identifying early signs of covert left ventricular problems such as hypertrophy or dysfunction.
Members of the natriuretic peptide system, ANP and BNP, have been studied as possible markers of increased cardiovascular risk in several patient groups [6] [7] [8] [10] [11] [12] [13] . Studies have generally demonstrated the superiority of BNP as a potential marker in both non-uraemic [9] and uraemic subjects [11, 17] and, although adequately powered head-to-head comparisons of N-BNP and BNP are limited, it would appear that N-BNP provides similar information to BNP [18] . In non-uraemic patients, BNP has been shown to act as a diagnostic marker for heart failure, left ventricular hypertrophy, left ventricular systolic dysfunction, diastolic dysfunction and conditions associated with right ventricular dysfunction, such as cor pulmonale, as well as being a predictor of mortality in heart failure, postacute myocardial infarct, unstable angina, cor pulmonale and primary pulmonary hypertension [10] . Natriuretic peptides have also been shown to have prognostic value among unselected members of the community, therefore suggesting that they may be elevated before the onset of clinically apparent disease. In the Framingham Offspring Study [8] for example, plasma levels of BNP and Nterminal pro-ANP strongly predicted heart failure and atrial fibrillation, with additional important associations with death from any cause, stroke or transient ischaemic attack and first major CV events.
In the present study, Cox regression analysis demonstrated pre-existing CV disease and log N-BNP as independent predictors of overall mortality or CV events in this population. There was no significant association with baseline treatment (ACEi, ARB or diuretic). The possible association between level of renal function and log N-BNP was addressed by including log creatinine as a covariate in the multiple regression analysis for predicting CV events or overall mortality. Even with these adjustments, log N-BNP remained an independent predictor of CV events or overall mortality. Furthermore, as there was a clear relationship between event rate and the baseline level of renal function for the KaplanMeier analysis, we stratified the population according to baseline creatinine levels above and below the median (225 µmol/l) (Figure 2) . The plasma N-BNP level was a differentiating factor in the outcomes only in the patients with more severely impaired renal function (serum creatinine above the median 225 µmol/l). A similar finding was observed with respect to the ability of N-BNP to predict the composite end point of doubling of creatinine, dialysis, death and CV events where log 10 N-BNP was a significant independent predictor of the composite end point at supra-median creatinine levels. One possible explanation is that there is a certain level of renal dysfunction above which the burden of asymptomatic CV disease significantly increases, and N-BNP might be able to provide added prognostic information in these patients. Indeed, it has been suggested by the ARIC (Atherosclerosis Risk in Communities) study [19] that the cut-off point where an excess CV burden begins in CKD is at a glomerular filtration rate level of 60 ml · min −1 ·1.73 m −2 . Patients with the end points of CV events/overall mortality were not all treated with therapeutic agents proven to reduce events such as ACEi and statins. Less than half of the subjects identified at high risk of CV events/death by virtue of N-BNP above the cut-off value of 355 pmol/l were on these agents, suggesting there was scope for optimization of therapy. It is perhaps worthwhile highlighting that none of the patients in the present study was diabetic for which there are clear well-accepted guidelines on the use of therapeutic agents such as ACEi, ARB, statins and aspirin. N-BNP levels might therefore be useful in selecting those non-diabetic CKD patients who require a more aggressive treatment approach. An unexpected finding of the present study was that N-BNP also appeared to be an independent predictor of renal disease progression. One possible explanation would be that the risk factors determining the progression of renal disease are similar to those with high CV risk.
Previously, three studies have examined BNP as a potential prognostic marker for cardiovascular mortality in dialysis-dependent ESRD. Zoccali et al. [11] examined a cohort of 246 dialysis patients without heart failure and found that BNP was an independent predictor of death in a Cox regression analysis, including left ventricular mass and ejection fraction. A second paper involving 112 dialysis patients reported that the BNP level was significantly higher in patients who died of cardiovascular causes compared with survivors and was significantly associated with greater risk of cardiovascular death in Cox regression analysis [12] . Finally, a study investigating the pathophysiological significance of BNP in haemodialysis patients found that, after stepwise multivariate Cox proportional hazards analysis, BNP, LVMI and CRP were powerful independent predictors of cardiac death [13] . There has been less information on the utility of plasma BNP in pre-dialysis CKD patients, although a recent study of 103 pre-dialysis CKD patients [14] has shown that plasma BNP is the strongest predictor for heart failure events by means of multivariate Cox regression analysis.
One of the obvious limitations of the present study is the absence of echocardiographic assessment of LV geometry and function. Previous studies have verified that the ability of N-BNP to predict CV events and death was related to its association with increased left ventricular mass or ventricular dysfunction. In the Framingham Offspring Study [8] , adjustment for echocardiographic variables attenuated the associations of log BNP and most outcomes, although the major outcomes remained statistically significant. However, previous studies investigating the prognostic utility of BNP in dialysis patients have shown on multivariate analyses (which included LVMI and left ventricular ejection fraction as covariates) that BNP was still an independent predictor of CV death [11, 12] . This could be a reflection of the recognized limitations of echocardiography, particularly with respect to the identification of abnormal ventricular filling pressures, for example in the presence of diastolic dysfunction. This observation would support the assertion that a simple inexpensive blood test to measure plasma N-BNP or BNP could be considered as an alternative means of risk assessment to echocardiographic examinations in the majority of uncomplicated CKD patients. N-BNP could be useful as a screening test in high-risk groups which might enable the selection of patients who could safely be excluded from further complex investigations, resulting in better focusing of resources.
The present study raises the possibility that measurement of plasma N-BNP may aid in the early detection of CV disease and risk stratification in pre-dialysis CKD patients. However, it is clear that larger studies with longer periods of follow-up are needed to validate our findings. Further studies are also warranted to determine whether aggressive management of CV risk factors (which overlap to some extent with factors promoting renal disease progression) can attenuate N-BNP levels and translate into an observed improved CV outcome for patients with CKD.
